[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053420":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":42,"collaborators":7,"id":44,"slug":7,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"XEOS Medical","INDUSTRY",null,[9,26],{"facility":10,"status":11,"city":12,"state":7,"zip":7,"country":13,"cosmosGeoPoint":14,"geoPoint":19,"contacts":20},"AZ Maria Middelares","RECRUITING","Ghent","Belgium",{"type":15,"coordinates":16},"Point",[17,18],3.71667,51.05,{"lat":18,"lon":17},[21],{"name":22,"role":23,"phone":24,"phoneExt":7,"email":25},"Dr. Ameye","CONTACT","+32 9 246 18 52","klinische.studies@mijnziekenhuis.be",{"facility":27,"status":11,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":36,"contacts":37},"University Hospitals Coventry and Warwickshire (UHCW) NHS Trust","Coventry","West Midlands","CV2 2DX","United Kingdom",{"type":15,"coordinates":33},[34,35],-1.51217,52.40656,{"lat":35,"lon":34},[38],{"name":39,"role":23,"phone":40,"phoneExt":7,"email":41},"Oludolapo Adesanya, Dr.","+44 2476 964000","Uhcw.Research3@uhcw.nhs.uk",{"type":43,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100053420",false,"NCT06970275","To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.","A Multicentric, Observational, Post-marketing, Registry Study to Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.","PETRiS","Inclusion Criteria :\n\nAll patients that were scheduled for resective surgery and for whom successful high-resolution PET-CT imaging was performed on their resected specimens using the AURA 10 PET-CT. Successful imaging means that the image contains at least a portion of the primary tumor, the radiotracer injection was correctly executed and there were no technical issues that lead to an uninterpretable PET-CT image. Or all patients that are scheduled for resective surgery and for whom high-resolution PET-CT imaging will be performed on their resected specimens using the AURA 10 PET-CT.\n\nPatients willing to provide informed consent for use of their relevant medical records. For retrospectively included patients with no further Long-Term Follow-Up (LTFU) data collection, a notification will be sent.\n\nExclusion Criteria:\n\n* Under the age of 18 years at the time of resective surgery.\n* Women who are pregnant or breastfeeding.","ALL","18 Years",{"count":54,"type":55},850,"ESTIMATED","OBSERVATIONAL","This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings. Additionally, it assesses how these imaging insights influence clinical decision-making and long-term patient outcomes. Through this comprehensive analysis in a real-world setting, the study seeks to generate valuable insights that can enhance specimen evaluation processes and ultimately improve patient care.",[59,60,61,62],"Prostate Cancers","Breast Cancer","Head and Neck Cancer","Cancer",[64,65,66,67],"PET-CT","Registry","Imaging","cancer","2026-07-10",{"date":70,"type":71},"2026-07-13","ACTUAL",{"date":73,"type":71},"2025-11-19",{"date":75,"type":55},"2031-01-15",{"name":5,"class":6},2]